Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LDLR | P01130 | 1/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.42 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.42 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.42 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.42 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.42 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.42 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.42 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217047 | 0.95 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL27217262 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL27217188 | 0.86 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL27216939 | 0.79 | BACE1 (0.39) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL27216960 | 0.78 | CYP2C9 (0.48) | CYP1A2CYP3A4CYP2D6HPGDSCYP2C9 | |
| SCHEMBL27217268 | 0.77 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL2315881 | 0.74 | HPGDS (0.59) | HPGDSKMT2AMEN1TDP1 | |
| SCHEMBL7871808 | 0.74 | HTR2A (0.45) | CYP1A2CYP3A4CYP2D6HPGDSGAA | |
| SCHEMBL27217027 | 0.73 | RPS6KB1 (0.36) | CYP1A2CYP3A4CYP2D6HPGDS | |
| SCHEMBL27217057 | 0.73 | HPGDS (0.38) | CYP1A2CYP3A4CYP2D6HPGDSTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | CYP1A2 3467/4885CYP3A4 3790/4885CYP2D6 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.